Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission
10.3760/cma.j.issn.0253-2727.2016.09.006
- VernacularTitle:利妥昔单抗追加治疗对初次完全缓解的弥漫大B细胞淋巴瘤患者的疗效评估
- Author:
Huijuan ZHONG
1
;
Pengpeng XU
;
Weili ZHAO
Author Information
1. 200025,上海交通大学医学院附属瑞金医院血液科
- Keywords:
Lymphoma,large B-cell,diffuse;
Rituximab;
Additional two cycles of administration
- From:
Chinese Journal of Hematology
2016;37(9):756-761
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy of additional two cycles ofrituximab administration for Chinese patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) after six cycles of standard 21-day rituximab plus cyclophosphamide,doxorubicin,vincristine and prednisone (R-CHOP21).Methods Retrospective analysis was performed in 351 patients with DLBCL diagnosed from March 2003 to March 2012.International Prognosis Index (IPI),Revised (R)-IPI and National Comprehensive Cancer Network (NCCN)-IPI were calculated for each patient.Patients were divided into GCB and non-GCB subtype according to Han's Classification.Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier methods.Results 282 (80.3％) patients achieved CR and 132 (46.8％) of 282 cases received additional two rituximab therapy.The other 150 (53.2％) patients entered into observation on the intention of the patients.No significant difference was observed in baseline characteristics between the two groups.3-year estimated PFS for additional rituximab group and observation group were 80.0％ and 78.1％ (P=0.334),while 3-year estimated OS were 89.7％ vs.86.1％ (P=0.452).By subgroup analysis,prolonged PFS were observed in R-IPI low-risk and NCCN-IPI low-risk patients after additional two rituximab cycles.Conclusion For patients with DLBCL in first remission after standard six cycles of R-CHOP21 regimen,additional two cycles of rituximab maintenance did not significantly improve the general prognosis,but low-risk subgroups of R-IPI and NCCN-IPI could benefit from this regimen.
